Document is current

Article History

Received: 22 June 2023

Accepted: 6 July 2023

First Online: 20 July 2023

Declarations

:

: Not applicable.

: Not applicable.

: Paolo A. Ascierto (PAA): Employment or Leadership Position: None; Consultant/Advisory Role: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna; Stock Ownership: None; Research Funding: Bristol-Meyers Squibb, Roche-Genentech, Pfizer, Sanofi; Expert Testimony: None; Other Remuneration: None. Antonio Avallone (AA): in the past two years, consulting or advisory role with: Amgen, MSD, Merck-Serono, Eisai, Astra-Zeneca. Carlo Bifulco (CB): Scientific Advisory Board & Stock Ownership: PrimeVax, BioAI; Scientific Advisory Board: Lunaphore; Scientific Advisory: Sanofi, Agilent; Patents: 10,275,880; 10,552,960; 11,164,316: Image processing systems and methods for displaying multiple images of a biological specimen & Image processing method and system for analyzing a multi-channel image obtained from a biological tissue sample being stained by multiple stains; Patent pending: 20200388033: System and method for automatic labeling of pathology images. Sergio Bracarda (SB): (Un.) Adv. Board or Steering Committee Member for: Pfizer, BMS, MSD, Roche, Astellas, Janssen, Ipsen, Bayer, AAA, Sanofy-Genzyme, Merck, AstraZeneca. Joshua D. Brody (JDB): nothing to disclose. Leisha A. Emens (LAE): in the past two years she has received research funding or provided consulting activities as listed below from the following sources: Research Funding (to institution): Genentech, F Hoffman La Roche, EMD Serono, Merck, AstraZeneca, Tempest, Bolt, Silverback, Takeda, CytomX, Compugen, Abbvie, BMS, Next Cure, Immune Onc; Consulting Activities: F Hoffman La Roche, Genentech, Macrogenics, Lilly, Chugai, Silverback, Shionogi, CytomX, GPCR, Immunitas, Astrazeneca, DNAMx, Gilead, Mersana. Immutep, and Bioline Rx; Dr. Emens also has potential ownership interest in Molecuvax; Leadership:President, Society for Immunotherapy of Cancer; Employment: Ankyra Therapeutics effective December 1, 2022 (potential for future stock options). Robert L. Ferris (RLF): AstraZeneca/ MedImmune: Clinical Trial, Research Funding; Bristol Myers Squibb: Advisory Board, Clinical Trial, Research Funding; EMD Serono: Advisory Board; MacroGenics, Inc: Advisory Board; Merck: Advisory Board, Clinical Trial; Novasenta: Stock, Consulting, Research Funding; Numab Therapeutics AG: Advisory Board; Pfizer: Advisory Board; SIRPant: Stock, Consulting; Tesaro: Research Funding. Silvia C. Formenti (SCF): Consultant for: Bayer, Bristol Myers Squibb, Varian, ViewRay, Accuray, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, AstraZeneca, MedImmune, Merck US, EMD Serono/Merck, Genentech/Roche, Boehringer Ingelheim, Nanobiotix; Grant/Research support from: Bristol Myers Squibb, Varian, Regeneron, Merck, Celldex. Omid Hamid (OH): Consulting / Advisory Boards: Alkermes, Amgen, Bactonix, Beigene, Bioatla, BMS, Esai Biotech, Roche Genentech, Georgiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instilbio, IO Biotech, Iovance, Janssen, KSQ, Merck, Moderna, Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial Health Tech, Zelluna. Speaker Bureaus: BMS, Immunocore, Novartis, Pfizer, Regeneron, Stock: Bactonix Contracted Research for Institution: Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, Cytomx, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck Serono, Nextcure, Novartis, Pfizer, Regeneron, Seattle Genetics, Torque, Zelluna. Douglas B. Johnson (DBJ): has served on advisory boards or as a consultant for BMS, Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, Targovax, and Teiko, has received research funding from BMS and Incyte, and has patents pending for use of MHC-II as a biomarker for immune checkpoint inhibitor response, and abatacept as treatment for immune-related adverse events. Tomas Kirchhoff (TK): nothing to disclose. Christopher A. Klebanoff (CAK): in the past two years I have received the funding listed below from the following sources: Advisory and consulting: Achilles Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Catamaran Bio, Obsidian Therapeutics, PACT Pharma, Genentech, T-knife; Research Support: Kite/Gilead, Intima Bioscience; Clinical Research Support: Kite/Gilead (Inst); Patent filings/royalties: PIK3CA, RAS G12D, and <u>RAS</u> <u>Q61</u> public NeoAg-specific TCRs, NeoAg TCR discovery platform. Gregory B. Lesinski (GBL): Dr. Lesinski is a Consultant to Annate Biotechnology; In 2017–2019 received Research Funding through Emory University from the following: Merck, Inc.<b>,</b> Vaccinex, Inc., Boehringer-Ingelheim, Inc., Bristol-Myers Squibb, Inc. Anne Monette (AM): nothing to disclose. Bart Neyns (BN): Bristol-Myers Squibb (the academic work I will present was conducted independently), MSD, Pierre-Fabre, Novartis, Amgen. Kunle Odunsi (KO): he has received the funding from: AstraZeneca and Tesaro. Scientific Advisory Boards: Daiichi-Sanyo. Co-founder: Tactiva Therapeutics. Chrystal M. Paulos (CMP): Ares Immunotherapy, Cue Therapeutics, KITE, Lycera, Obsidian, Orange Grove Bio, ThermoFisher, Vaccinex. Daniel J. Powell Jr. (DJP): holds patents on tumor infiltrating lymphocyte selection, as well as TCR and CAR constructs. He receives royalties for licensing of intellectual properties related to TIL, TCR and CAR technologies, as well as fees for advisory services from InsTIL Bio on TIL therapy and Bellicum Pharmaceuticals on CAR T cell therapy. Katayoun Rezvani (KR): and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical and with Affimed GmbH. KR participates on the Scientific Advisory Board for GemoAb, AvengeBio, Virogin Biotech, GSK, Bayer, Navan Technologies, and Caribou Biosciences. KR is the scientific founder of Syena. Brahm H. Segal (BHS): Sponsored Research: Apellis, Next Cure; Scientific Advisory Board: Next Cure. Ryan J. Sullivan (RJS): he has received the funding listed below from the following sources: Merck; Novartis; Pfizer; BMS. Bernard A. Fox (BAF): Scientific Advisory Board (Advising/Consulting): Akoya/PerkinElmer, AstraZeneca/Definiens, Bristol-Myers Squibb, CanWell, Hookipa, Incyte, Macrogenics, NeoGenomics, PrimeVax (BOD, stock), Turnstone, UbiVac, Co-founder/CEO/stock, Ultivue; Research Support: Akoya/PerkinElmer, Bristol-Myers Squibb, Definies/AstraZeneca, Incyte, Macrogenics, NanoString, OncoSec Shimadzu, Viralytics/Merck. Igor Puzanov (IP): Research Funding: NIH/NCI P30CA016056 Cancer Center Support Grant Program Leader, 1.2 Calendar Months; CoCsulting/Advisory: Nouscom, Iovance, Nektar, Regeneron.